Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    7 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T05:10:52.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    Revision: v3.4.3 is now displayed, replacing the previous Revision: v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-12T00:00:45.000Z thumbnail image
  4. Check
    22 days ago
    No Change Detected
  5. Check
    43 days ago
    Change Detected
    Summary
    A new site revision tag 'Revision: v3.4.2' was added, and the previous banner about government funding and the older revision 'v3.4.1' were removed.
    Difference
    0.4%
    Check dated 2026-02-11T14:19:39.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    A site-wide notice about a lapse in government funding was added, and the page version updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T10:25:15.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    The page now displays a glossary and includes new metadata sections (Last Update Submitted that Met QC Criteria and Last Update Posted), plus a No FEAR Act Data notice and Revision: v3.4.0. The previous items (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4) are removed.
    Difference
    0.2%
    Check dated 2026-01-28T06:17:45.000Z thumbnail image
  8. Check
    72 days ago
    Change Detected
    Summary
    Revision: v3.3.4 added and Revision: v3.3.3 removed; this appears to be a backend release update with no visible changes to the study page.
    Difference
    0.0%
    Check dated 2026-01-14T02:58:23.000Z thumbnail image

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.